Long-term remission in a patient with refractory thrombotic thrombocytopenic purpura treated with rituximab and plasma exchange [1]

Annals of Hematology

Volumn 87, Issue 4, 2008, Pages 321-323

  Basquiera, A L ^a,b   Damonte, J C ^a   Abichain P ^a   Sturich, A G ^a   Garcia J J ^a  

^a HOSPITAL PRIVADO   (Argentina)

^b NONE   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FRESH FROZEN PLASMA; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ANEMIA; ATOPIC DERMATITIS; BLOOD SMEAR; CASE REPORT; CLINICAL EXAMINATION; CONFUSION; CONJUNCTIVAL HEMORRHAGE; DYSARTHRIA; ECCHYMOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; JAUNDICE; LETTER; NEUROLOGIC DISEASE; PARESTHESIA; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC FACTORS; PLASMA EXCHANGE; PLATELET COUNT; PURPURA; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 41249097556     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0384-5     Document Type: Letter

References (12)

1. Allford SL, Hunt BJ, Rose P, Machin S (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemias. Br J Haematol 120:556-573
2. Darabi K, Berg AH (2006) Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 125:592-597
3. Fakhouri F, Vernant JP, Veyradier A et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 106:1932-1937
4. Galbusera M, Bresin E, Noris M et al (2005) Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report. Blood 106:925-928
5. George JN, Woodson RD, Kiss JE, Kojouri K, Vessely SK (2006) Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21:49-56
6. Klaus C, Plaimauer B, Studt JD et al (2004) Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 103:4514-4519
7. Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M (2007) A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. J Thromb Thrombolysis 23:147-150
8. Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393-397
9. Scully M, Cohen H, Cavenagh J et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451-461
10. Sperr WR, Lechner K, Pabinger I (2007) Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 92:66-71
11. Tsai H-M, Lian ECY (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585-1594
12. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 103:4043-4049